EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

Ailsa Hart, Seyedehsan Navabi iD, Geert D'Haens, Katsuyoshi Matsuoka, María Dolores Martín-Arranz iD, Raja Atreya iD, Karen Hamrick Samaan, Endip Dhesi, Isabel Redondo, Baojin Zhu, Jerome Paulissen, Liliana Zaremba-Pechmann und 4 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70214 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Ailsa Hart und 15 weiteren Autor:innen. Beteiligte Einrichtung: St Mark's Hospital & Imperial College London, London, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Colitis, Ulcerative, Maintenance Chemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.

Methods

LUCENT‐1 patients received 300 mg mirikizumab or placebo; mirikizumab induction responders entered LUCENT‐2 and received 200 mg mirikizumab or placebo until week (W)52. Mirikizumab induction non‐responders received extended induction with open‐label 300 mg mirikizumab between W12 and W24. Extended induction responders received open‐label 200 mg mirikizumab between W24 and W52. In each population, efficacy was analyzed by subgroups based on PATF number (0, 1, ≥ 2 [2–3]) and mechanism (including difficult‐to‐treat [DTT]: anti‐TNF plus tofacitinib and/or vedolizumab).

Results

At baseline, 479/1162 patients (41.2%) had (≥ 1) PATF, of which 177 (37.0%) had DTT. Among mirikizumab‐treated patients ( n = 868), W12 clinical response was achieved by 69.8%, 63.9%, 45.3%, and 41.9% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups, respectively. 42.1% (365/868) continued with maintenance treatment. Among W12 responders, 51.9% (0‐PATF), 44.2% (1‐PATF), 49.0% (≥ 2‐PATF), and 42.9% (DTT) achieved clinical remission at W52. Over half of the patients (54.0% [147/272]) in the extended induction population had PATF; 51.0% (75/147) were DTT. At W24, clinical response was achieved by 62.4%, 41.4%, 49.5%, and 49.3% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups. Of this 49.3% of the DTT subgroup (extended induction responders), 38.9% (14/36) achieved W52 clinical remission.

Conclusions

Mirikizumab induction and maintenance is efficacious in moderately‐to‐severely active ulcerative colitis with or without prior failure of advanced therapy, including difficult‐to‐treat disease. Trail Registration LUCENT‐1: NCT03518086; LUCENT‐2: NCT03524092

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsColitis, UlcerativeMaintenance ChemotherapyInduction ChemotherapyEndoscopy, GastrointestinalTreatment OutcomeSeverity of Illness IndexIntention to Treat AnalysisDouble-Blind MethodHumansMaleFemaleAdultMiddle Aged

Stichwörter der Autor:innen

advanced therapybiologicdifficult‐to‐treatmirikizumabulcerative colitis

Substanzen

mirikizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • St Mark's Hospital & Imperial College London, London, UK.
  • United Medical Doctors, Long Beach, California, USA.
  • Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Toho University Sakura Medical Center, Sakura, Japan.
  • Department of Gastroenterology of La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, Hospital La Paz Institute for Health Research, La Paz Hospital, Madrid, Spain.
  • First Department of Medicine, University Hospital Erlangen, University of Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Seyedehsan Navabi, María Dolores Martín-Arranz, Raja Atreya, David Laharie

Förderung

  • Eli Lilly and Company

Zitieren

APA

Hart, A., Navabi, S., D'Haens, G., Matsuoka, K., Martín-Arranz, M. D., Atreya, R., Samaan, K. H., Dhesi, E., Redondo, I., Zhu, B., Paulissen, J., Zaremba-Pechmann, L., Baygani, S., Limdi, J., Laharie, D., & Danese, S. (2026). Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70214

Vancouver

Hart A, Navabi S, D'Haens G, Matsuoka K, Martín-Arranz MD, Atreya R, et al. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70214

BibTeX
@article{Hart2026,
  author = {Hart, Ailsa and Navabi, Seyedehsan and D'Haens, Geert and Matsuoka, Katsuyoshi and Martín-Arranz, María Dolores and Atreya, Raja and Samaan, Karen Hamrick and Dhesi, Endip and Redondo, Isabel and Zhu, Baojin and Paulissen, Jerome and Zaremba-Pechmann, Liliana and Baygani, Simin and Limdi, Jimmy and Laharie, David and Danese, Silvio},
  title = {Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70214}
}
Kostenlos starten →